Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

DRUG(4)
OTHER(1)
MIXED(1)
PROCEDURE(1)
N-acetyl-L-cysteine
3 trials
phase_2phase_3
peking-university-peoples-hospital
Chemotherapy
1 trial
phase_3
peking-university
Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid
1 trial
phase_3
peking-university-peoples-hospital
haplotype PBSCT
1 trial
peking-university-peoples-hospital
Nanobody-Based CD19/CD22 Tandem Dual CAR-T
1 trial
phase_1_2
peking-university-peoples-hospital
Haplo-identical HSCT
1 trial
phase_3
peking-university
6 unique interventions5 categories

Analytics

Trial Phases

Phase 11
Phase 23
Phase 33

Trial Status

Completed2
Recruiting1
Other4

Role Distribution

Principal Investigator7
PI Rate100%

Activity Timeline

Clinical Trials (7)

NCT06880913Phase 1/2Recruiting
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
PrincipalinvestigatorStart date: 2024-11-14
NCT06024031Phase 2Active Not Recruiting
NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy
Acute Myeloid Leukemia
PrincipalinvestigatorStart date: 2023-09-10
NCT03756675Unknown
Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Leukemia
Acute Leukemia
PrincipalinvestigatorStart date: 2018-11-01
NCT03967665Phase 3Unknown
Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution
Stem Cell Transplant Complications
PrincipalinvestigatorStart date: 2018-10-01
NCT03236220Phase 2Completed
Effect of NAC on the Hematopoietic Reconstitution After Haploidentical Hematopoietic Stem Cell Transplantation
Haploidentical Hematopoietic Stem Cell Transplantation
PrincipalinvestigatorStart date: 2017-08-01
NCT02042690Phase 3Completed
Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients
Acute Lymphoblastic Leukemia
PrincipalinvestigatorStart date: 2014-07-01
NCT04175587Phase 3Unknown
Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL
Acute Promyelocytic Leukaemia
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Qifa Liu

Nanfang Hospital, Southern Medical University

Related
33 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteAcute LeukemiaPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Worked with same sponsors:

Peking University People's HospitalUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Similarity Score13%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Acute LeukemiaLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Similarity Score13%

Beata Holkova, MD

Massey Cancer Center

Related
3 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, Acute
Similarity Score9%

Brigitte C Widemann, M.D.

National Cancer Institute (NCI)

Related
19 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, Acute
Similarity Score9%

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, Acute
Similarity Score9%

Areej El-Jawahri, MD

Massachusetts General Hospital

Related
21 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteStem Cell Transplant Complications
Similarity Score9%

Jorge Cortes, MD

M.D. Anderson Cancer Center

Related
24 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Similarity Score9%

Mitchell S Cairo, MD

New York Medical College

Related
13 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Similarity Score9%

Farhad Ravandi-Kashani, MD

M.D. Anderson Cancer Center

Related
14 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Similarity Score9%

Jorge E Cortes, MD

M.D. Anderson Cancer Center

Related
8 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Similarity Score9%

Publications (0)

No publications found for this investigator.

Clinical Trials (7)

Showing 7 of 7 trials

NCT06880913Phase 1/2PrincipalInvestigator

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Recruiting
NCT06024031Phase 2PrincipalInvestigator

NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy

Acute Myeloid Leukemia
Active Not Recruiting
NCT03756675PrincipalInvestigator

Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Leukemia

Acute Leukemia
Unknown
NCT03967665Phase 3PrincipalInvestigator

Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution

Stem Cell Transplant Complications
Unknown
NCT03236220Phase 2PrincipalInvestigator

Effect of NAC on the Hematopoietic Reconstitution After Haploidentical Hematopoietic Stem Cell Transplantation

Haploidentical Hematopoietic Stem Cell Transplantation
Completed
NCT02042690Phase 3PrincipalInvestigator

Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients

Acute Lymphoblastic Leukemia
Completed
NCT04175587Phase 3PrincipalInvestigator

Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL

Acute Promyelocytic Leukaemia
Unknown

All 7 trials loaded